IP Verse

Gilead Sciences competitive analysis

Latest publications and patents of Gilead Sciences New

Explore the latest publications and patents granted to Gilead Sciences, showcasing their recent innovations and technological advancements.

Last updated on: Sep 18, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Gilead Sciences

EP4232463
Sep 3, 2025Interleukin-2-Fc Fusion Proteins And Methods Of UseGranted And Under Opposition
EP4244396
Aug 13, 2025Methods Of Identifying Hiv Patients Sensitive To Therapy With Gp120 Cd4 Binding Site-Directed AntibodiesGranted And Under Opposition
EP3595667
Dec 20, 2023Pharmaceutical Compositions Comprising A Jak InhibitorGranted And Under Opposition
EP2655623
Aug 30, 2023Non-Coding Immunomodulatory Dna ConstructPatent Maintained As Amended
EP4070788
Mar 22, 2023Pharmaceutical FormulationsGranted And Under Opposition
EP4070787
Mar 1, 2023Pharmaceutical FormulationsGranted And Under Opposition
EP2937350
Aug 17, 20221' -Substituted Carba-Nucleoside Analogs For Antiviral TreatmentNo Opposition Filed Within Time Limit
EP2709613
Aug 12, 2020Methods For Treating HcvPatent Maintained As Amended
EP3150586
Jan 8, 2020Modulators Of Pharmacokinetic Properties Of TherapeuticsGranted And Under Opposition
EP3346995
Aug 28, 2019Therapeutic Compositions For Treatment Of Human Immunodeficiency VirusGranted And Under Opposition

Latest oppositions filed by Gilead Sciences

Explore patent oppositions filed by Gilead Sciences against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 25, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3854403
Use Of Substituted Aminopropionate Compounds In Treatment Of Sars-Cov-2 InfectionACADEMY OF MILITARY MEDICAL SCIENCESJun 18, 2025
EP2399588
Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral PolymeraseIONIS PHARMACEUTICALSJan 7, 2021
EP3284520
Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory ActivitySHIONOGIFeb 4, 2020
EP2955190
Chemical CompoundsNUCANADec 17, 2018
EP3045206
Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory ActivitySHIONOGIDec 6, 2018

Latest patents of Gilead Sciences opposed by its competitors

Explore Gilead Sciences's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3595667
Dec 20, 2023Pharmaceutical Compositions Comprising A Jak Inhibitor3
EP2655623
Aug 30, 2023Non-Coding Immunomodulatory Dna Construct1
EP4070788
Mar 22, 2023Pharmaceutical Formulations1
EP4070787
Mar 1, 2023Pharmaceutical Formulations1
EP2709613
Aug 12, 2020Methods For Treating Hcv1
EP3150586
Jan 8, 2020Modulators Of Pharmacokinetic Properties Of Therapeutics3
EP3346995
Aug 28, 2019Therapeutic Compositions For Treatment Of Human Immunodeficiency Virus3
EP3157932
Jan 10, 2018Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5]Pyrazino [2, 1-B]Oxazepin-8-Olate1
EP2682397
Apr 19, 2017Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same3
EP2637664
Mar 29, 2017Compositions And Methods Of Treating Pulmonary Hypertension6

Latest PTAB cases involving Gilead Sciences

Discover the latest PTAB cases involving Gilead Sciences, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 24, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Gilead Sciences

IPR2025-00033Oct 28, 2024CIPLAGILEAD SCIENCESInstitution Denied
PGR2023-00046Aug 7, 2023ATEA PHARMACEUTICALSGILEAD SCIENCESInstitution Denied
IPR2019-01456Aug 23, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2019-01455Aug 23, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2019-01454Aug 21, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2019-01453Aug 21, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2017-02005Aug 29, 2017GILEAD SCIENCESREGENTS OF THE UNIVERSITY OF MINNESOTAInstitution Denied
IPR2017-02004Aug 28, 2017GILEAD SCIENCESREGENTS OF THE UNIVERSITY OF MINNESOTAInstitution Denied
IPR2017-01753Jul 7, 2017GILEAD SCIENCESREGENTS OF THE UNIVERSITY OF MINNESOTAInstitution Denied
IPR2017-01712Jun 30, 2017GILEAD SCIENCESREGENTS OF THE UNIVERSITY OF MINNESOTAFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Gilead Sciences with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
GILEAD SCIENCES52386Balanced
COOKE27 - - - Highly Aggressive
MYLAN PHARMACEUTICALS - - 94 - Highly Aggressive
REGENTS OF THE UNIVERSITY OF MINNESOTA - 5 - 11Non-Active